The trades put some of Ark's better-known holdings on the sell side, including AMD, Alphabet, and SpaceX, while its genomics-focused ARK Genomic Revolution ETF continued to add to biotech companies.

On Friday, Outlook Therapeutics (OTLK), a biopharmaceutical company developing and commercializing LYTENAVA for retinal diseases, announced Greg DiPasquale as Chief Commercial Officer. Greg DiPasquale ...

Harari argues that AI and biotech will treat humans as algorithms and may replace the humanist faith behind modern rights and ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company ...

HTBA, a Barcelona-based manufacturer of citrus flavonoids and vitamin B12, has acquired U.S. biotech company Specnova, which ...

Gandhinagar: Gujarat has proposed a ₹100-crore investment over five years to develop a Marine Biotechnology Research and ...

Bhopal: Madhya Pradesh is stepping up efforts to attract pharmaceutical, biotechnology and medical device investments, with ...

Biotechnology company Obatala Sciences has selected Charleston County for its first East Coast operation, a move expected to ...

From Alzheimer’s drugs to smarter irrigation, Marin Sonoma Impact Ventures’ new $11 million fund is backing the next wave of ...

The leaders discussed opportunities to connect Montana’s research institutions, clinics, and bioscience companies with ...

DBT-BET has been merged with Life Sciences. Check the new Life Sciences & Biotechnology discipline and details of the revised syllabus.